C5 and atypical hemolytic-uremic syndrome: Inhibiting activation of C5, and thus the generation of C5a and MAC, has shown great therapeutic benefit in complement-driven inflammatory diseases, such as atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) (9, 10).